GlassScriptPhysician profile
Michael J Derosa
NPI 1568499283
$4,412.34
in general payments reported to CMS, 2019-2025
44 companies · $328 in 2025
The $328 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $798 · 2020: $222 · 2021: $791 · 2022: $1,173 · 2023: $766 · 2024: $334 · 2025: $328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,343 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,343.06 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $593.99 | 2019-2023 | Ubrelvy, Lo Loestrin Fe |
| Gynesonics, INC. | $323.39 | 2022-2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Therapeuticsmd, INC. | $292.31 | 2019-2022 | |
| Astellas Pharma US INC | $238.33 | 2023-2025 | Veozah, Myrbetriq |
| Hologic Sales and Service, LLC | $201.00 | 2019-2024 | Thinprep 2000 Processor, Aptima, Third Wave |
| Bayer Healthcare Pharmaceuticals INC. | $181.46 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $181.27 | 2021-2025 | |
| Organon LLC | $165.04 | 2022-2025 | Nexplanon, Jada System |
| Sumitomo Pharma America, INC. | $163.47 | 2023-2025 | Myfembree |
| Meditrina | $155.71 | 2021-2023 | |
| Pfizer INC. | $149.80 | 2019-2025 | |
| Duchesnay USA Incorporated | $144.54 | 2019 | |
| Agile Therapeutics, INC. | $140.35 | 2021-2023 | Twirla |
| Exeltis, USA INC. | $133.02 | 2021-2025 | Slynd |
| Allergan, INC. | $126.17 | 2019-2020 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aspira Women'S Health INC | $101.61 | 2022 | |
| Evofem Biosciences, INC. | $101.43 | 2021 | |
| Myovant Sciences INC. | $97.15 | 2021-2022 | |
| Novo Nordisk INC | $85.83 | 2019-2025 | Wegovy |
| Avion Pharmaceuticals | $80.44 | 2019-2023 | Balcoltra |
| Exact Sciences Corporation | $77.26 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $58.22 | 2019-2020 | |
| Covidien LP | $51.42 | 2019-2020 | |
| Amgen INC. | $49.86 | 2019-2024 | Prolia, Evenity |
| Lupin INC. | $48.77 | 2020-2021 | |
| Mylan Pharmaceuticals INC. | $41.49 | 2022 | |
| Amag Pharmaceuticals, INC. | $37.88 | 2019 | |
| Shield Therapeutics INC | $34.76 | 2022 | |
| Conmed Corporation | $33.93 | 2024 | Visiclear, Airseal |
| Sage Therapeutics, LLC | $31.88 | 2021-2025 | Zurzuvae |
| Takeda Pharmaceuticals U.S.A., INC. | $31.72 | 2021 | |
| Aesculap, INC. | $29.88 | 2019 | |
| Vertical Pharmaceuticals, LLC | $27.99 | 2019 | |
| Smith+Nephew, INC. | $24.82 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.02 | 2022 | |
| Coopersurgical, INC. | $21.60 | 2023 | Wallach Cryosurgical Equipment |
| Monaghan Medical Corporation | $21.46 | 2023 | Aerobika |
| Supernus Pharmaceuticals, INC. | $18.15 | 2025 | Qelbree |
| Minerva Surgical, INC | $17.28 | 2025 | |
| Optumhealth Care Solutions, LLC | $15.54 | 2025 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Scynexis, INC. | $15.51 | 2022 | |
| Lsi Solutions INC | $14.54 | 2024 | Fornisee |
| Mission Pharmacal Company | $14.26 | 2020 | |
| Boston Scientific Corporation | $13.79 | 2025 | Bulkamid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Derosa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.